Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Carcinoma, Anaplastic 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 10Iodine-131 8selpercatinib 5Thyrotropin Alfa 5trametinib 4dabrafenib 4Vemurafenib 4Thyroidectomy 4lenvatinib 3cabozantinib 3Transurethral Resection of Prostate 3Sunitinib 3Specimen Handling 3Sorafenib 3Radiofrequency Ablation 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2entrectinib 2cobimetinib 2X-Rays 2Trastuzumab 2Thyroid (USP) 2Surgical Procedures, Operative 2Rosiglitazone 2Radiotherapy 2Nivolumab 2Lymph Node Excision 2Interviews as Topic 2Gefitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Taxes × Endocrine × Clear all
NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Purple Biotech Ltd.

Phase 1/2 Completed
79 enrolled
DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡